Alsahl Group is a leading global enterprise with extensive operations spanning Asia, Europe, and North America. We offer a comprehensive suite of R&D and manufacturing services designed to propel the international pharmaceutical and life sciences sectors forward. Our mission is to facilitate the advancement of scientific discoveries and the development of novel treatments that significantly improve patient outcomes. At Alsahl Group, our integrated, end-to-end solutions encompass a wide range of capabilities, including Contract Research, Development, and Manufacturing Organization (CRDMO) services for chemistry-based drug development, biology discovery, preclinical and clinical research, as well as Contract Testing, Development, and Manufacturing Organization (CTDMO) services for advanced therapies. Our commitment to enhancing healthcare productivity is demonstrated through our cost-effective, efficient approaches and our AA ESG rating from MSCI, achieved for the third consecutive year in 2023. Our open-access platform supports over 6,000 clients from more than 30 countries, empowering them to address significant health challenges and fulfill our vision: “Every drug can be made, and every disease can be treated.”